The Trump administration has negotiated 15 deals in which pharmaceutical companies voluntarily agreed to lower prices on prescription medications in the United States.
The negotiations broke the long-standing practice by manufacturers of charging up to 400 percent more for brand-name drugs in the United States than in Canada, the UK, and other developed nations.





